BioLineRx to Report Third Quarter 2012 Results on November 14, 2012

  BioLineRx to Report Third Quarter 2012 Results on November 14, 2012

             Management to hold conference call at 9:00 a.m. EST

Business Wire

JERUSALEM -- November 05, 2012

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development
company, announced today that it will release its unaudited financial results
for the quarter ended September 30, 2012 on Wednesday, November 14, 2012,
before the U.S. markets open.

The Company will host a conference call on Wednesday, November 14 at 9:00 a.m.
EST featuring remarks by Kinneret Savitsky, Ph.D., CEO of BioLineRx, and
Philip Serlin, Chief Financial and Operating Officer of BioLineRx. The
conference call will be available via webcast and can be accessed through the
Investor Relations section of BioLineRx’s website, www.biolinerx.com, and
www.kcsa.com. Please allow extra time prior to the call to visit the site and
download any necessary software to listen to the live broadcast. To dial into
the conference call, please dial 1-888-407-2553 from the U.S. or
+972-3-918-0610 internationally.

A replay of the conference call will be available approximately two hours
after completion of the live conference call at www.biolinerx.com or
www.kcsa.com. A dial-in replay of the call will be available until November
17, 2012; please dial 1-877-456-0009 from the U.S. or +972-3-9255925
internationally.

About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet medical
needs or with advantages over currently available therapies. BioLineRx’s
current portfolio consists of six clinical stage candidates: BL-1020 for
schizophrenia is currently undergoing a Phase II/III study; BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to Ikaria Inc., is currently
undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical
removal of skin lesions has completed a Phase I/II study; BL-1021 for
neuropathic pain is in Phase I development, BL-7040 for treating inflammatory
bowel disease (IBD) currently undergoing a Phase II trial, and BL-8040 for
treating acute myeloid leukemia (AML) and other hematological cancers has
completed Phase I. In addition, BioLineRx has nine products in various
pre-clinical development stages for a variety of indications, including
central nervous system diseases, infectious diseases, cardiovascular and
autoimmune diseases.

BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company performs
feasibility assessment studies and development through pre-clinical and
clinical stages, with partial funding from the Israeli Government’s Office of
the Chief Scientist (OCS). The final stage includes partnering with medium and
large pharmaceutical companies for advanced clinical development (Phase III)
and commercialization. For more information on BioLineRx, please visit
www.biolinerx.com.

Contact:

KCSA Strategic Communications
Garth Russell, 1-212-896-1250
grussell@kcsa.com
or
Todd Fromer, 1-212-896-1215
tfromer@kcsa.comor
or
Tsipi Haitovsky, Public Relations
+972-52-598-9892
tsipih@netvision.net.il
 
Press spacebar to pause and continue. Press esc to stop.